You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

PROPYLTHIOURACIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Propylthiouracil patents expire, and what generic alternatives are available?

Propylthiouracil is a drug marketed by Abbott, Actavis Elizabeth, Anabolic, Ani Pharms, Chartwell Molecular, Chartwell Rx, Endo Operations, Halsey, Impax Labs, Lilly, Macleods Pharms Ltd, Quagen, Sun Pharm Industries, Tablicaps, and Watson Labs. and is included in sixteen NDAs.

The generic ingredient in PROPYLTHIOURACIL is propylthiouracil. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the propylthiouracil profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Propylthiouracil

A generic version of PROPYLTHIOURACIL was approved as propylthiouracil by QUAGEN on December 31st, 1969.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PROPYLTHIOURACIL?
  • What are the global sales for PROPYLTHIOURACIL?
  • What is Average Wholesale Price for PROPYLTHIOURACIL?
Summary for PROPYLTHIOURACIL
Drug patent expirations by year for PROPYLTHIOURACIL
Drug Prices for PROPYLTHIOURACIL

See drug prices for PROPYLTHIOURACIL

Recent Clinical Trials for PROPYLTHIOURACIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Case Comprehensive Cancer CenterPhase 2
Maastricht UniversityPhase 2
Maastricht UniversityPhase 1

See all PROPYLTHIOURACIL clinical trials

Pharmacology for PROPYLTHIOURACIL
Medical Subject Heading (MeSH) Categories for PROPYLTHIOURACIL

US Patents and Regulatory Information for PROPYLTHIOURACIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott PROPYLTHIOURACIL propylthiouracil TABLET;ORAL 084075-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Endo Operations PROPYLTHIOURACIL propylthiouracil TABLET;ORAL 006188-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Ani Pharms PROPYLTHIOURACIL propylthiouracil TABLET;ORAL 080215-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

PROPYLTHIOURACIL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Propylthiouracil

Introduction to Propylthiouracil

Propylthiouracil (PTU) is an antithyroid medication used primarily to treat hyperthyroidism and Graves' disease. It works by inhibiting the synthesis of thyroid hormones, making it a crucial drug in managing thyroid disorders.

Market Size and Growth

The global propylthiouracil market is anticipated to experience significant growth over the coming years. Here are some key statistics:

  • The global propylthiouracil market size is expected to grow from approximately USD 300 million in 2023 to around USD 420 million by 2032, at a compound annual growth rate (CAGR)[4].
  • Another forecast indicates that the propylthiouracil market could reach $3,000 million by 2026, growing at a CAGR of 10% from 2021 to 2026[1].

Market Segmentation

The thyroid gland disorder treatment market, which includes propylthiouracil, is segmented in several ways:

  • By Drug Type: Propylthiouracil is one of the segments within the broader thyroid gland disorder treatment market, which also includes levothyroxine, liothyronine, imidazole-based compounds, and beta-blockers. The levothyroxine segment dominates this market, but propylthiouracil holds a significant share[3].
  • By Disease: The market is segmented into hypothyroidism and hyperthyroidism. Hyperthyroidism, for which propylthiouracil is a treatment, is a substantial segment within this market[3].
  • By Route of Administration: The oral route is the most common for propylthiouracil and other thyroid disorder treatments, with this segment anticipated to reach USD 2.4 billion by 2032[3].
  • By Distribution Channel: The market is segmented into wholesalers/distributors, retail chains, online distribution, and other channels. Wholesalers/distributors hold a substantial revenue share[3].

Regional Market

Geographically, the thyroid gland disorder treatment market, including propylthiouracil, is diverse but has significant concentrations in certain regions:

  • North America: This region held a significant market share of 40.7% in 2023 and is predicted to witness substantial growth over the analysis period[3].

Competitive Landscape

The thyroid gland disorder treatment market, including propylthiouracil, is competitive with several large multinationals and small to mid-sized companies:

  • Key market players are focused on developing and launching novel advanced products based on different technologies. This competitive environment drives innovation and market growth[3].

Clinical Use and Recommendations

Treatment of Hyperthyroidism

Propylthiouracil is used to treat hyperthyroidism, a condition where the thyroid gland produces too much thyroid hormone. It is particularly recommended for patients who have not responded well to other treatments like methimazole[2].

Use During Pregnancy

Propylthiouracil is recommended as the first-line treatment for hyperthyroidism during pregnancy due to the potential risks associated with methimazole, such as fetal developmental abnormalities[5].

Side Effects and Precautions

While propylthiouracil is effective, it comes with several potential side effects and precautions:

  • Liver Problems: Patients should be monitored for signs of liver problems, such as upper right abdominal pain, dark urine, and yellow eyes or skin[2].
  • Blood Cell Count: The drug can lower white blood cell and platelet counts, increasing the risk of infections and bleeding[2].
  • Pregnancy and Breastfeeding: Use during pregnancy requires careful monitoring, and while breastfeeding, the drug poses minimal risk to the infant[2].

Technological Advancements

The pharmaceutical industry, including the segment for thyroid disorder treatments, is witnessing significant technological advancements:

  • Improved Drug Delivery: Innovations in drug delivery systems are enhancing the bioavailability and efficacy of medications like propylthiouracil[3].
  • Targeted Therapies: The development of targeted therapies is another area of advancement, offering more precise and effective treatment options for thyroid disorders[3].

Financial Projections

The financial trajectory for propylthiouracil is positive, driven by several factors:

  • Growing Demand: Increasing prevalence of thyroid disorders and the need for effective treatments contribute to the growing demand for propylthiouracil[3].
  • Market Expansion: The market is expected to expand due to rising healthcare expenditure globally and increased investment in the diagnosis and treatment of thyroid disorders[3].

Key Takeaways

  • The propylthiouracil market is expected to grow significantly, reaching USD 420 million by 2032.
  • The drug is a crucial treatment for hyperthyroidism and is particularly recommended during pregnancy.
  • The market is segmented by drug type, disease, route of administration, and distribution channel.
  • North America holds a significant market share, and technological advancements are driving market growth.
  • Careful monitoring is required due to potential side effects, especially liver problems and blood cell count issues.

FAQs

What is propylthiouracil used for?

Propylthiouracil is used to treat hyperthyroidism and Graves' disease by inhibiting the synthesis of thyroid hormones.

Why is propylthiouracil recommended during pregnancy?

Propylthiouracil is recommended during pregnancy because it has a lower risk of fetal developmental abnormalities compared to other antithyroid medications like methimazole.

What are the potential side effects of propylthiouracil?

Potential side effects include liver problems, lowered white blood cell and platelet counts, and various symptoms such as fever, chills, and skin rashes.

How is the propylthiouracil market segmented?

The market is segmented by drug type, disease (hypothyroidism and hyperthyroidism), route of administration (primarily oral), and distribution channel.

What is the projected market size for propylthiouracil by 2032?

The global propylthiouracil market is expected to reach approximately USD 420 million by 2032.

Sources

  1. IndustryARC: Propyl Thiouracil Market - Forecast(2024 - 2030) - IndustryARC
  2. Mayo Clinic: Propylthiouracil (oral route) - Mayo Clinic
  3. GMI Insights: Thyroid Gland Disorder Treatment Market Trends Report, 2032
  4. DataIntelo: Propylthiouracil Ptu Market Research Report 2032 - Dataintelo
  5. Oxford University Press: Management of Thyroid Dysfunction during Pregnancy and the Postpartum Period - Journal of Clinical Endocrinology & Metabolism[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.